Monocytes engineered with iSNAP inhibit human B-lymphoma progression.
CD47
Don't eat me signal
cancer immunotherapy
engineering monocytes
macrophage polarization
Journal
Bioengineering & translational medicine
ISSN: 2380-6761
Titre abrégé: Bioeng Transl Med
Pays: United States
ID NLM: 101689146
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
22
08
2021
revised:
25
11
2021
accepted:
06
12
2021
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Monocytes are important regulators for the maintenance of homeostasis in innate and adaptive immune system and have been reported to play important role in cancer progression. CD47-SIRPα recognition is a coinhibitory immune signal to inhibit phagocytosis in monocytes and macrophages and has been well-known as the "Don't eat me" signal. By using an approach of integrated sensing and activating proteins (iSNAPs), we have rewired the CD47-SIRPα axis to create iSNAP-M which activates pathways in engineered human monocytes (iSNAP-MC). The mRNA expression levels of the monocyte/macrophage markers CD11b, CD14, and CD31 are upregulated in iSNAP-monocytes (iSNAP-MC). With PMA induction, the iSNAP-MC-derived macrophages (iSNAP-MΦ) showed upregelation in CD86 and CD80, but not CD206. TNFα expression and secretion were also increased in iSNAP-MΦ. Furthermore, the injection of iSNAP-MC into mice bearing human B-lymphoma tumors led to the suppression of tumor progression. Therefore, the engineered monocytes, via blockage of coinhibitory immune signals by rewiring CD47-SIRPα axis, can be applied to suppress target tumors for cancer immunotherapy.
Identifiants
pubmed: 35600645
doi: 10.1002/btm2.10285
pii: BTM210285
pmc: PMC9115687
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10285Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM126016
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM140929
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM125379
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD107206
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL121365
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB029122
Pays : United States
Informations de copyright
© 2021 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of The American Institute of Chemical Engineers.
Déclaration de conflit d'intérêts
Yingxiao Wang is a scientific cofounder of Cell E&G and Acoustic Cell Therapy, Inc. Other authors declare no conflict of interests.
Références
Nat Commun. 2017 Sep 7;8(1):477
pubmed: 28883531
Immunotherapy. 2017 Mar;9(3):289-302
pubmed: 28231720
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):180-185
pubmed: 26621196
Immunol Today. 1994 Oct;15(10):490-5
pubmed: 7945775
Curr Biol. 2017 Jul 24;27(14):2065-2077.e6
pubmed: 28669759
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819849068
pubmed: 31088266
Nat Biotechnol. 2020 Aug;38(8):947-953
pubmed: 32361713
Chem Immunol. 2000;74:61-82
pubmed: 10608082
Eur J Cancer. 2017 May;76:100-109
pubmed: 28286286
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
Hepatology. 2013 Aug;58(2):680-91
pubmed: 23504854
Ann Oncol. 2018 Nov 1;29(11):2163-2174
pubmed: 30295695
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
J Biol Chem. 2005 Jan 14;280(2):1336-45
pubmed: 15485828
J Leukoc Biol. 2017 Jul;102(1):31-40
pubmed: 28522599
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Immunol Lett. 2014 Jul;160(1):1-10
pubmed: 24698728
Ann Transl Med. 2021 Apr;9(8):709
pubmed: 33987407
Bull Math Biol. 2015 Oct;77(10):1934-54
pubmed: 26481497
Cancer Microenviron. 2013 Aug;6(2):179-91
pubmed: 23179263
Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43
pubmed: 29253115
Immunol Rev. 2015 Jan;263(1):68-89
pubmed: 25510272
Nat Biotechnol. 2013 Jan;31(1):71-5
pubmed: 23242161
PLoS One. 2017 Jul 27;12(7):e0182039
pubmed: 28750018
Cell. 2018 Oct 4;175(2):442-457.e23
pubmed: 30290143
Nat Biomed Eng. 2018 Aug;2(8):559-561
pubmed: 31015640
Adv Drug Deliv Rev. 2017 May 15;114:79-101
pubmed: 28545888
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Cancer Med. 2019 Aug;8(9):4245-4253
pubmed: 31183992
Clin Cancer Res. 2018 Dec 15;24(24):6185-6194
pubmed: 30097433
J Immunol. 2017 Jan 1;198(1):31-39
pubmed: 27994166
Adv Mater. 2019 Dec;31(51):e1904364
pubmed: 31659802
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
Curr Pharm Biotechnol. 2018;19(1):5-18
pubmed: 29667553
Annu Rev Immunol. 2005;23:901-44
pubmed: 15771589
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Immunol Rev. 2014 Nov;262(1):36-55
pubmed: 25319326
Cell Stem Cell. 2018 Aug 02;23(2):181-192.e5
pubmed: 30082067